Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
 Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease…
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest…